Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Editas Medicine, Inc. (EDIT)

Capricor Therapeutics, Inc. and Editas Medicine, Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. and Editas Medicine, Inc. are of similar size ($455.2M and $445.4M). Editas Medicine, Inc. grew revenue faster over the last twelve months: 20.8% against −11.6%. Capricor Therapeutics, Inc. has the higher net margin (0.00% vs −157.3%) and the lower return on invested capital (−1,019.7% vs 0.00%). Across the 16 metrics below, Capricor Therapeutics, Inc. leads on 8 and Editas Medicine, Inc. on 8.

Valuation

Metric CAPR EDIT Biotechnology median
P/E n/m n/m 8.56
P/S 19.43 6.98 10.17
P/B 1.76 3.12 2.34
Price to free cash flow 3.31 n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 9.38 3.17 9.64
Earnings yield (32.80%) (27.27%) (29.41%)
Free cash flow yield 30.25% (36.66%) (23.50%)

Profitability

Metric CAPR EDIT Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (161.39%) 0.00%
Net margin 0.00% (157.32%) 0.00%
Free cash flow margin 0.00% (255.88%) 0.00%
Return on equity (73.70%) (118.82%) (56.66%)
Return on assets (51.53%) (33.02%) (49.22%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR EDIT Biotechnology median
Revenue growth (TTM) (11.55%) 20.83% 5.64%
EPS growth (last fiscal year) (96.52%) 37.50% 30.08%
Revenue growth, 5-year CAGR 85.83% (14.89%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR EDIT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 3.19 4.72
Net debt to EBITDA 2.99 0.94 0.96

Dividend

Metric CAPR EDIT Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CAPR EDIT Biotechnology median
Market cap 455.23m 445.38m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack